Cancer burden in slovenia with the time trends analysis

Zadnik, Vesna; Žakelj, Maja Primic; Lokar, Katarina; Jarm, Katja; Ivanuš, Urška; Žagar, Tina

doi:10.1515/raon-2017-0008

Cited by 67 publications

(74 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study showed that the disease burden of cancer was mainly on people aged from 50 to 70. Vesna Zadnik et al found that the main financial burden—which increased with age—was on the elderly population and for both male and female, cancer was predominant in people aged from 50 to 74,21 presenting results similar to ours. However, for cancer control in the future, cancer prevention and control measures cannot be carried out only among the elderly population.…”

Section: Discussionsupporting

confidence: 87%

How great is current curative expenditure and catastrophic health expenditure among patients with cancer in China? A research based on “System of Health Account 2011”

et al. 2018

View full text Add to dashboard Cite

In recent years, the incidence and mortality of cancer have witnessed a dramatic increase. Cancer has already caused severe economic burdens on society, especially in developing countries and has become a major public health concern. This study evaluates the medical economic burden, including total current curative expenditure (CCE) and catastrophic health expenditure (CHE) on cancer in Liaoning Province, China. A total of 252 medical institutions were investigated with multistage stratified cluster random sampling. We established a standardized database of 3 532 517 samples. “System of Health Account 2011”, a new internationally recognized accounting system, was established to analyze the CCE on six most common cancers. CHE were estimated from the extracted 1344 patients with cancer, which performed a cross‐sectional study. The association of individual and contextual factors with CHE was evaluated using logistic regression models. CCE for all the patients with the six types of cancer was 2801.38 million CNY in Liaoning Province, the highest of which was lung cancer. The incidence of CHE was 42.78%, while the threshold was 40%. The average and relative distance were 10.41% and 24.32%, respectively. Influencing factors were length of stay, type of health insurance, location of household, etc. Our findings highlight the need to address medical economic burden in the cancer population. Households with the cancer are more likely to incur CHE. Financial intervention to prevent it should target on poor households. We provide suggestions in aspects of health insurance and health service management to reduce CHE.

show abstract

Section: Discussionsupporting

confidence: 87%

How great is current curative expenditure and catastrophic health expenditure among patients with cancer in China? A research based on “System of Health Account 2011”

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Locally advanced non-small cell lung cancer (LA-NSCLC) patients represent one third of all patients with NSCLC. 1 Approximately 70% of NSCLC patients in stage III have inoperable disease. Standard treatment for these patients is concurrent chemoradiotherapy (CCRT).…”

Section: Introductionmentioning

confidence: 99%

Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy

Vrankar

Stanič

2018

Radiology and Oncology

View full text Add to dashboard Cite

BackgroundStandard treatment for patients with inoperable locally advanced non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy (CCRT). Five-year overall survival rates range between 15 and 25%, while long term survival data are rarely reported.Patients and methodsA total of 102 patients with stage III NSCLC treated between September 2005 and November 2010 with induction chemotherapy and CCRT were included in this long term survival analysis. All patients were tested for PD-L1 status and expression of PD-L1 was correlated with overall survival (OS), progression free survival (PFS) and toxicities.ResultsThe median OS of all patients was 24.8 months (95% CI 18.7 to 31.0) with 10 year-survival rate of 11.2%. The median OS of patients with PD-L1 expression was 12.1 months (95% CI 0.1 to 26.2), while in patients with negative or unknown PD-L1 status was significantly longer, 25.2 months (95% CI 18.9 to 31.6), p = 0.005. The median PFS of all patients was 16.4 months (95% CI 13.0 to 19.9). PFS of patients with PD-L1 expression was 10.1 months (95% CI 0.1 to 20.4) and in patients with negative or unknown PD-L1 status was 17.9 months (95% CI 14.2 to 21.7), p = 0.003.Conclusions10-year overall survival of stage III NSCLC patients after CCRT is 11.2%. PFS and OS differ with regard to PD-L1 status and are significantly shorter for patients with PD-L1 expression. New treatment with check-point inhibitors combined with RT therefore seems reasonable strategy to improve these results.

show abstract

“…Melanoma incidence is on the 6 th place among all the cancers in Slovenia and it is constantly rising during last period. 1 , 2 Although early melanoma has a good prognosis, melanoma with distant metastasis carries a high mortality rate. 3 Until recently there was a lack of successful treatment approach in metastatic melanoma.…”

Section: Introductionmentioning

confidence: 99%

Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma

Moltara

Novaković

Boc

et al. 2018

Radiology and Oncology

Self Cite

View full text Add to dashboard Cite

BackgroundBRAF, NRAS and c-KIT mutations are characteristics of tumour tissues that influence on treatment decisions in metastatic melanoma patients. Mutation frequency and their correlation with histological characteristics in Slovenian population have not been investigated yet.Patients and methodsIn our retrospective analysis we analysed mutational status of BRAF, NRAS and c-KIT in 230 pathological samples of patients who were intended to be treated with systemic therapy due to metastatic disease at the Institute of Oncology Ljubljana between 2013 and 2016. We collected also histological characteristics of primary tumours and clinical data of patients and correlated them with mutational status of tumour samples.ResultsThe study population consisted of 230 patients with a mean age 59 years (range 25−85). 141 (61.3%) were males and 89 (38.7%) females. BRAF mutations were identified in 129 (56.1%), NRAS in 31 (13.5%) and c-KIT in 3 (1.3%) tissue samples. Among the 129 patients with BRAF mutations, 114 (88.4%) patients had V600E mutation and 15 (11.6%) had V600K mutation. Patients with BRAF mutations tended to be younger at diagnosis (52 vs. 59 years, p < 0.05), patients with NRAS mutations older (61 vs. 55 years, p < 0.05). Number of c-KIT mutations were too low for any statistical correlation, but there was one out of 3 melanoma located in mucus membranes.ConclusionsThe analysis detected high rate of BRAF mutations, low NRAS mutations and low c-KIT mutations compared to previously published studies in Europe and North America. One of the main reasons for this observation is specific characteristics of study population.

show abstract

Cancer burden in slovenia with the time trends analysis

Cited by 67 publications

References 12 publications

How great is current curative expenditure and catastrophic health expenditure among patients with cancer in China? A research based on “System of Health Account 2011”

How great is current curative expenditure and catastrophic health expenditure among patients with cancer in China? A research based on “System of Health Account 2011”

Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy

Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma

Contact Info

Product

Resources

About